Dolby Laboratories, Inc. — Q1 Fiscal 2016 Form 10-Q
Reporting period: Fiscal quarter ended January 1, 2016. The quarter covered 14 weeks, compared with 13 weeks in the prior-year quarter ended December 26, 2014; the additional week increased some expenses and limits comparability. Amounts below are in U.S. dollars.
Financial performance and liquidity
| Metric | Q1 FY2016 | Prior-year quarter | Change |
|---|---|---|---|
| Revenue | $240.8 million | $234.2 million | +2.8% |
| Gross margin | $211.0 million; 87.6% | $214.8 million; 91.7% | Amount -1.8%; margin down |
| Operating income | $39.2 million; 16.3% margin | $53.5 million; 22.9% margin | -26.8% |
| Net income attributable to Dolby | $30.9 million | $41.4 million | -25.3% |
| Diluted EPS | $0.30 | $0.40 | Down $0.10 |
| Cash from operating activities | $67.4 million | $3.4 million | Up $64.0 million |
- Revenue mix: Licensing was $211.1 million, down 2.5%; products were $24.8 million, up 87%; services were $4.9 million, up 11%. Management attributed licensing weakness mainly to timing in mobile arrangements and lower PC and consumer-electronics units, partly offset by broadcast recoveries and higher TV volumes, gaming-console shipments, and Via Licensing revenue. Product growth primarily reflected cinema server, 3D glasses, and cinema-audio shipments.
- Costs and margins: Total cost of revenue rose 53% to $29.8 million. Licensing cost increased largely due to amortization of newly acquired intangible assets; product margin improved with sales mix and lower excess-inventory charges. R&D rose 10% to $53.3 million and sales and marketing rose 9% to $74.5 million, including costs related to the new headquarters, added headcount, and growth initiatives.
- Cash and working capital: Cash and cash equivalents were $467.1 million; short- and long-term investments totaled $406.0 million. Working capital was $541.4 million. Cash, cash equivalents, and investments together were approximately $873.1 million, down from $991.8 million at September 25, 2015. Operating cash flow benefited from timing-related working-capital changes, including lower receivables and higher deferred revenue.
- Debt and liquidity: The filing does not report borrowings or a debt balance. Total liabilities were $301.4 million. Management said cash, investments, and operating cash flows should meet anticipated cash requirements for at least the next 12 months. Approximately 60% of cash and investments were held by foreign subsidiaries; repatriation could incur U.S. and foreign taxes.
- Capital returns and investment: Dolby repurchased 1.14 million shares for $39.4 million and paid $12.1 million in dividends during the quarter. The remaining repurchase authorization was approximately $113.3 million. Capital expenditures were $24.4 million.
Material changes and unusual items
- Dolby paid $105.0 million for a patent portfolio on September 30, 2015, recorded as an intangible asset and to be amortized over a weighted-average useful life of nine years. Intangible assets, net, increased to $224.2 million from $127.5 million at fiscal year-end.
- Other expense worsened, primarily because of higher foreign-currency translation losses. The effective tax rate decreased to 21% from 23%, reflecting greater federal R&D tax-credit benefits, partly offset by the IRS audit settlement for tax years 2011 and 2012.
- There were no restructuring charges in the quarter. The prior-year quarter included an immaterial restructuring credit.
- The quarter’s results include the effects of the additional fiscal week. The company cautions that quarterly results are not necessarily indicative of future periods.
Outlook, risks, and contingencies
- The filing provides no numerical revenue or earnings guidance. Management highlighted efforts to expand Dolby Atmos, Dolby Vision, Dolby Cinema, and Dolby Voice, while noting that commercial adoption, partner deployments, content availability, and consumer demand remain uncertain.
- Key business risks include reliance on licensees’ product shipments and royalty reporting; declining PC and optical-disc markets; competition and pricing pressure; patent expirations and unauthorized use of intellectual property; and the need to establish new products and business models. Dolby also cited execution and adoption risks for Dolby Cinema and other newer initiatives.
- Dolby said the Korean Fair Trade Commission review resulted in changes to future standard licensing terms without an admission of liability or wrongdoing. China’s NDRC review was resolved on mutually agreeable terms, with implementation ongoing. Other ordinary-course legal proceedings were not expected by management to materially affect results, but an unfavorable outcome could have a material effect in a particular period; the filing does not provide a clear estimate of potential losses.
- Contractual commitments totaled $237.1 million, including $137.8 million for theatre naming rights and $78.3 million for operating leases. Dolby could not reasonably estimate maximum exposure under certain intellectual-property indemnification clauses and had accrued no amount for those contingencies.
- The Dolby family and affiliates held 90.4% of combined voting power at January 1, 2016, reflecting the ten-votes-per-share Class B structure.
Important facts for investors to verify
- Whether licensing revenue recovers from mobile timing effects and ongoing PC and consumer-electronics market pressures, and how much reported licensing revenue depends on recoveries.
- Whether growth in cinema products and new initiatives can offset licensing softness and sustain gross margins after the patent-purchase amortization.
- Cash generation and investment balances, including foreign-held funds, planned repurchases and dividends, and the $105.0 million patent acquisition’s returns.
- Progress and financial impact of Dolby Cinema, Dolby Vision, Dolby Voice, and Dolby Atmos deployments; the filing gives no numerical outlook for these initiatives.
- Developments in competition-law matters, licensing disputes, tax contingencies, and other legal proceedings; certain possible exposures are not quantifiable in the filing.